HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecular heterogeneity in mucoepidermoid carcinoma: conceptual and practical implications.

Abstract
Mucoepidermoid carcinoma (MEC), the most common salivary gland malignancy of the upper aerodigestive tract and tracheobronchial tree, is also known for its considerable cellular heterogeneity including epidermoid, intermediate and mucin producing cells. Despite this structural and cellular heterogeneity, MEC is uniquely characterized by a specific translocation t(11; 19) (q12; p13), resulting in a fusion between the MECT1 and the MAML2 genes. Although the incidence of this fusion in MEC varies, it is generally accepted that more than 50 % of this entity manifest the MECT1-MAML2. Fusion-positive cases showed significantly better survival than fusion-negative cases, suggesting that MECT1-MAML2 represents a specific prognostic molecular marker in MEC. We contend that fusion in MEC represents a distinct mechanism in the development of this entity. In that context, fusion positive MEC, regardless of grade, manifest a more stable genome and better clinical behaviour, while fusion negative MEC represent a distinctly different pathway characterized by marked genomic instability and relatively aggressive tumors.
AuthorsDiana Bell, Adel K El-Naggar
JournalHead and neck pathology (Head Neck Pathol) Vol. 7 Issue 1 Pg. 23-7 (Mar 2013) ISSN: 1936-0568 [Electronic] United States
PMID23459841 (Publication Type: Journal Article, Review)
Chemical References
  • MECT1-MAML2 fusion protein, human
  • Oncogene Proteins, Fusion
Topics
  • Carcinoma, Mucoepidermoid (genetics, pathology)
  • Humans
  • Oncogene Proteins, Fusion (genetics)
  • Salivary Gland Neoplasms (genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: